Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018

Publication date: December 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 12Author(s): Liam R. Brunham, Isabelle Ruel, Sumayah Aljenedil, Jean-Baptiste Rivière, Alexis Baass, Jack V. Tu, G.B. John Mancini, Paolo Raggi, Milan Gupta, Patrick Couture, Glen J. Pearson, Jean Bergeron, Gordon A. Francis, Brian W. McCrindle, Katherine Morrison, Julie St-Pierre, Mélanie Henderson, Robert A. Hegele, Jacques Genest, Jeannette GoguenAbstractFamilial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are undiagnosed. Herein, we provide an update of the 2014 Canadian Cardiovascular Society position statement on FH addressing the need for case identification, prompt recognition, and treatment with statins and ezetimibe, and cascade family screening. We provide a new Canadian definition for FH and tools for clinicians to make a diagnosis. The risk of atherosclerotic cardiovascular disease in patients with “definite” FH is 10- to 20-fold that of a normolipidemic individual and initiating treatment in youth or young adulthood can normalize life expectancy. Target levels for low-density lipoprotein cholesterol are proposed and are aligned with the Canadian Cardiovascular Society guidelines on dyslipidemia. Recommendation for the use of inhibitors of proprotein convertase kexin/subtilisin type ...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research